We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $429M
1-Year Est. Return 52.52%
This Fund
S&P 500
This Quarter Est. Return
+23.54%
1 Year Est. Return
+52.52%
3 Year Est. Return
+172.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$429M
AUM Growth
+$66.7M
Cap. Flow
+$19.4M
Cap. Flow %
4.52%
Top 10 Hldgs %
7.64%
Holding
517
New
67
Increased
228
Reduced
168
Closed
54

Top Buys

Rank Stock Value
1
DVN icon
Devon Energy
DVN
+$3.47M
2
DDOG icon
Datadog
DDOG
+$2.53M
3
MRVL icon
Marvell Technology
MRVL
+$2.28M
4
WDC icon
Western Digital
WDC
+$2.19M
5
NTAP icon
NetApp
NTAP
+$2.17M

Top Sells

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$2.17M
2
LIN icon
Linde
LIN
+$2.08M
3
HSY icon
Hershey
HSY
+$2.06M
4
LYV icon
Live Nation Entertainment
LYV
+$1.97M
5
KO icon
Coca-Cola
KO
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 38.77%
2 Technology 15.15%
3 Financials 13.21%
4 Industrials 12.74%
5 Consumer Discretionary 5.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELC icon
301
Celcuity
CELC
$4.06B
$387K 0.09%
3,695
+1,106
+43% +$128K
NKTR icon
302
Nektar Therapeutics
NKTR
$2.27B
$385K 0.09%
5,510
+526
+11% +$38.5K
CSWC icon
303
Capital Southwest
CSWC
$1.52B
$384K 0.09%
16,171
-6,293
-28% -$147K
MSIF
304
MSC Income Fund Inc
MSIF
$560M
$384K 0.09%
33,217
-6,704
-17% -$82K
CMPS
305
Compass Pathways
CMPS
$1.96B
$383K 0.09%
27,086
-13,371
-33% -$136K
SVRA icon
306
Savara
SVRA
$1.07B
$383K 0.09%
62,205
+22,800
+58% +$122K
COGT icon
307
Cogent Biosciences
COGT
$5.69B
$383K 0.09%
9,885
+3,409
+53% +$119K
EWTX icon
308
Edgewise Therapeutics
EWTX
$4.82B
$382K 0.09%
9,395
-2,149
-19% -$74.1K
TSLX icon
309
Sixth Street Specialty
TSLX
$1.72B
$382K 0.09%
22,230
-4,399
-17% -$78.5K
ALMS
310
Alumis Inc
ALMS
$1.03B
$381K 0.09%
13,549
-10,183
-43% -$237K
RXRX icon
311
Recursion Pharmaceuticals
RXRX
$1.74B
$381K 0.09%
103,872
+40,897
+65% +$136K
ALT icon
312
Altimmune
ALT
$632M
$381K 0.09%
125,363
+73,620
+142% +$220K
XENE icon
313
Xenon Pharmaceuticals
XENE
$5.54B
$379K 0.09%
6,281
+93
+2% +$5.16K
SLRC icon
314
SLR Investment Corp
SLRC
$657M
$378K 0.09%
30,547
-788
-3% -$11K
IMNM icon
315
Immunome
IMNM
$2.74B
$377K 0.09%
17,802
+3,870
+28% +$82.8K
IMVT icon
316
Immunovant
IMVT
$7.65B
$375K 0.09%
9,732
-588
-6% -$17.9K
KOD icon
317
Kodiak Sciences
KOD
$2.07B
$374K 0.09%
9,606
-1,845
-16% -$71.8K
MLYS icon
318
Mineralys Therapeutics
MLYS
$2.45B
$374K 0.09%
13,853
+6,464
+87% +$177K
LBRX
319
LB Pharmaceuticals
LBRX
$1.38B
$374K 0.09%
+11,513
New +$338K
TRAX
320
First Tracks Biotherapeutics
TRAX
$1.4B
$373K 0.09%
+18,549
New +$347K
MSDL icon
321
Morgan Stanley Direct Lending Fund
MSDL
$1.24B
$373K 0.09%
24,668
-3,624
-13% -$54.9K
CLYM
322
Climb Bio
CLYM
$812M
$373K 0.09%
+28,602
New +$295K
AVBP icon
323
ArriVent BioPharma
AVBP
$1.36B
$372K 0.09%
10,714
-451
-4% -$13.3K
TECX
324
Tectonic Therapeutic
TECX
$562M
$371K 0.09%
10,806
-2,993
-22% -$87.9K
UPB
325
Upstream Bio Inc
UPB
$297M
$371K 0.09%
53,638
+43,592
+434% +$365K
11 12
13
14 15

Similar funds

MSG
Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return
NL
Navalign LLC Encino, California $429M AUM 18.12% 1-Year Est. Return
PG
Prostatis Group Hanover, Maryland $429M AUM 26.55% 1-Year Est. Return
LFGO
Legacy Financial Group (Oklahoma) Tulsa, Oklahoma $429M AUM 21.51% 1-Year Est. Return
SFWC
Strategic Family Wealth Counselors Fairfield, New Jersey $430M AUM 17.41% 1-Year Est. Return
RS
Rakuten Securities Tokyo, Japan $430M AUM 189.97% 1-Year Est. Return
T
TrueFG Cedar Park, Texas $428M AUM 21.6% 1-Year Est. Return
WBC
West Branch Capital Amherst, Massachusetts $430M AUM 41.9% 1-Year Est. Return

Virtus Investment Advisers's Q2 2026 Portfolio in Review

As of Q2 2026, Virtus Investment Advisers held 517 positions worth $429M, up 18% from $363M the previous quarter. Its ten largest holdings account for 7.6% of the portfolio.

Virtus Investment Advisers deployed $19.4M of net new capital in Q2 2026, opening 67 new positions and adding to 228 existing holdings. Its largest new stake was Devon Energy: 74,863 shares worth $3.09M.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, up from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was ImmunityBio, an estimated $1.47M trimmed.

  • Virtus Investment Advisers's largest Q2 2026 buy was Devon Energy: 74,863 shares worth $3.09M.
  • Virtus Investment Advisers added most to Omeros in Q2 2026, an estimated $1.26M increase.
  • Virtus Investment Advisers's biggest Q2 2026 reduction was ImmunityBio, cutting an estimated $1.47M.
  • Virtus Investment Advisers fully exited Day One Biopharmaceuticals in Q2 2026, selling an estimated $2.17M.
  • Virtus Investment Advisers's ten largest holdings make up 7.6% of its $429M portfolio in Q2 2026.
  • Virtus Investment Advisers opened 67 new positions and closed 54 in Q2 2026.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $429M.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.